Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-19
    E.g., 2018-10-19

Articles

Pages

4210 items
12:00 AM, Oct 31, 2016  |  BC Extra | Top Story

Third Rock closes fourth fund at $616M

Third Rock Ventures closed its Fund IV at $616 million, exceeding its $600 million target. The firm intends to launch or invest in 10-12 early stage companies focused on oncology, immunology, neurology, cardiovascular disease and...
12:00 AM, Oct 28, 2016  |  BC Extra | Top Story

Pricing woes pummel biopharma stocks

Biopharmas suffered sell-offs on Friday as investors digested concerns about drug pricing that affected the outlook for Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Amgen Inc. (NASDAQ:AMGN) and AbbVie Inc. (NYSE:ABBV). Novo lost more than $13 billion...
12:00 AM, Oct 27, 2016  |  BC Extra | Top Story

BMS rises on earnings, promise of cost containment

Along with reporting 3Q16 earnings that beat estimates and raising full-year guidance, Bristol-Myers Squibb Co. (NYSE:BMY) on Thursday announced it would keep non-GAAP operating expenses "roughly flat" in 2016-20, even as it increases R&D spending...
12:00 AM, Oct 26, 2016  |  BC Extra | Top Story

Biogen reports Tecfidera growth, ends S1P program

In its 3Q16 earnings report, Biogen Inc. (NASDAQ:BIIB) said sales of multiple sclerosis drug Tecfidera dimethyl fumarate grew 10% compared to 3Q15. The company also said it discontinued development of autoimmune candidate amiselimod ( MT-1303),...
12:00 AM, Oct 25, 2016  |  BC Extra | Top Story

Novartis says CAR T on track

Novartis AG (NYSE:NVS; SIX:NOVN) on Tuesday said it remains on track to submit a BLA to FDA early next year for its CTL019 chimeric antigen receptor (CAR) T cell therapy to treat pediatric acute lymphoblastic...
12:00 AM, Oct 24, 2016  |  BC Extra | Top Story

FDA approves Keytruda as first-line NSCLC therapy

Merck & Co. Inc. (NYSE:MRK) said late Monday FDA approved Keytruda pembrolizumab as a first-line treatment for metastatic non-small lung cancer patients with ≥50% PD-L1 expression and with no EGFR or anaplastic lymphoma kinase (ALK)...
12:00 AM, Oct 21, 2016  |  BC Extra | Top Story

Keytruda passes Phase III bladder cancer test

Merck & Co. Inc. (NYSE:MRK) said PD-1 mAb Keytruda pembrolizumab met the co-primary overall survival (OS) endpoint in the Phase III KEYNOTE-045 trial to treat bladder cancer. The pharma stopped the study early on the...
12:00 AM, Oct 20, 2016  |  BC Extra | Top Story

Alkermes rises after MDD therapy passes Phase III test

Alkermes plc (NASDAQ:ALKS) gained $19.47 (45%) to $62.98 in early after-hours trading Thursday after it said the higher of two doses of ALKS 5461 met the primary endpoint of the FORWARD-5 trial as an adjunctive...
12:00 AM, Oct 19, 2016  |  BC Extra | Top Story

FDA approves Lilly's Lartruvo for STS

FDA granted accelerated approval to Lartruvo olaratumab from Eli Lilly and Co. (NYSE:LLY) in combination with doxorubicin to treat advanced soft tissue sarcoma patients who cannot be cured with radiation or surgery and for whom...
12:00 AM, Oct 18, 2016  |  BC Extra | Top Story

LLS launches collaborative AML trial

On Tuesday, the Leukemia & Lymphoma Society launched the collaborative Phase IIa/IIb Beat AML trial, which will evaluate multiple candidates to treat first-line acute myelogenous leukemia. The trial will enroll newly diagnosed AML patients aged...

Pages